UK’s NICE to review guidance on Servier's Protelos after legal challenge
This article was originally published in SRA
The health technology appraisal body for England and Wales, NICE, will have to review its guidance on Servier's Protelos (strontium ranelate) for preventing osteoporotic fragility fractures, a UK appeals court judge has said1. Moreover, the National Institute for Health and Clinical Excellence must be clear in its reasoning when it reaches a different conclusion from that of "eminent bodies" such as the European Medicines Agency (EMA), according to the judgment.
You may also be interested in...
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
EFPIA, the European Federation of Pharmaceutical Industries and Associations, has put forward what it thinks the European regulatory network strategy to 2025 should prioritize.